Swedish Orphan Biovitrum AB (LTS:0MTD) Total Liabilities : kr38,616 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Total Liabilities?

Swedish Orphan Biovitrum AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr38,616 Mil.

Swedish Orphan Biovitrum AB's quarterly Total Liabilities declined from Sep. 2023 (kr41,138.00 Mil) to Dec. 2023 (kr40,160.00 Mil) and declined from Dec. 2023 (kr40,160.00 Mil) to Mar. 2024 (kr38,616.00 Mil).

Swedish Orphan Biovitrum AB's annual Total Liabilities increased from Dec. 2021 (kr25,458.00 Mil) to Dec. 2022 (kr25,971.00 Mil) and increased from Dec. 2022 (kr25,971.00 Mil) to Dec. 2023 (kr40,160.00 Mil).

Swedish Orphan Biovitrum AB Total Liabilities Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Total Liabilities Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

28,728.00

28,077.00

25,458.00

25,971.00

40,160.00

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															26,083.00	47,408.00	41,138.00	40,160.00	38,616.00

Swedish Orphan Biovitrum AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Swedish Orphan Biovitrum AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19095	+	(11524	+	9331
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	210)
	=	40,160

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	74027	-	33867
	=	40,160

Swedish Orphan Biovitrum AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17105	+	(11575	+	9936
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	38,616

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	74518	-	35902
	=	38,616

Swedish Orphan Biovitrum AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK B6E:Germany B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines